Ng Tat Ming

Principal Pharmacist (specialist), Tan Tock Seng Hospital

Research Interests:

- Infectious Disease Pharmacotherapy
- Physiologically-based Pharmacokinetics
- 3D printed pharmaceuticals

Email: tat.ming.ng@nhghealth.com.sg

Biography

Tat Ming is an infectious disease specialist pharmacist at Tan Tock Seng Hospital with an interest in advancing clinical care through research and innovation. He is currently working on physiologically-based pharmacokinetic applications to therapeutic drug monitoring and 3D printed pharmaceuticals in addition to infectious disease pharmacotherapy research. He received his Doctor of pharmacy degree in 2012 and completed the pharmacy infectious disease residency training in 2018.

Selected Publications

- Ng TM, Wang Z, Chan ECY. Physiologically-based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID-19. Br J Clin Pharmacol. 2025 Apr;91(4):1041-1048.

- Ng TM, Heng ST, Chua BH, Ang LW, Tan SH, Tay HL, Yap MY, Quek J, Teng CB, Young BE, Lin R, Ang B, Lee TH, Lye DC. Sustaining Antimicrobial Stewardship in a High-Antibiotic Resistance Setting. JAMA Netw Open. 2022 May 2;5(5):e2210180.

- Goh O, Goh WJ, Lim SH, Hoo GS, Liew R, Ng TM. Preferences of Healthcare Professionals on 3D-Printed Tablets: A Pilot Study. Pharmaceutics. 2022 Jul 21;14(7):1521.

- ST Heng, J Wong, B Young, HL Tay, SH Tan, MY Yap, CB Teng, B Ang, TH Lee, HL Tan, TW Lew, DC Lye, TM Ng. Effective Antimicrobial StewaRdship StrategIES (ARIES): Cluster randomised trial of computerised decision support system and prospective review and feedback. Open Forum Infectious Diseases 29 June 2020, ofaa254.

Notable Research Awards & Grants from Past 5 Years

Name of Awards & Grants	Year Obtained
NHG-LKC Clinician-Scientist Career Scheme Beta-Lactam levels and Outcomes of gram-negative Bacteraemia (BLOB-1	2021
NHG Centre for Medical Technologies & Innovations (CMTi) MedTech Grant Addressing aDherence and drug delivery with vAriable dose 3D printed combination oral PharmaceuTicals (ADAPT) – A proof of concept in anti-tuberculosis medications.	2022
NMRC Research Training Fellowship (RTF) Developing beta-lactam pharamcodynamic targets in gram negative bacteremia using physiologically based pharmacokinetic modelling (TARGET)	2023